NaturalShrimp Announces Filing of Joint Patent Application
NaturalShrimp, Inc. (OTCQB: SHMP) announced a joint patent application with Hydrenesis, Inc. to enhance its Intellectual Property (IP) protection for Electrocoagulation (EC) and HydroGas technologies. The new technologies demonstrate improved welfare scores in both shrimp and finfish, confirmed by third-party trials in Norway. This collaboration aims to strengthen the existing IP portfolio and license the technologies for various aquatic species, indicating the company's commitment to innovation and growth, as emphasized by leadership statements on production capabilities and shareholder value.
- Joint patent application to strengthen IP protection for EC and HydroGas technologies.
- Positive third-party trial results in shrimp and finfish welfare scores.
- Plans to license technologies for various aquatic species, expanding market potential.
- None.
Strengthens Intellectual Property (IP) Protection Related to Electrocoagulation (EC) and HydroGas Technologies
DALLAS, TX, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), and its technology partner, Hydrenesis, Inc., today announced the filing a United States joint patent application to further strengthen the Intellectual
Property (IP) protection related to Electrocoagulation (EC) and HydroGas technologies.
EC and Hydrogas have shown efficacy in improving welfare scores not only in shrimp production, but also in finfish, as evidenced by third party trials conducted at a leading aquaculture testing facility in Bergen, Norway. The newly filed patent application involves technology co-developed by NaturalShrimp and Hydrenesis as a strategy to augment existing IP protection with additional, and more advanced methods and apparatus. NaturalShrimp will license the EC and HydroGas technologies for various aquatic species.
“We are constantly looking for ways to improve efficiency and broad applications for our technologies, not just in shrimp, but also in additional aquatic species,” said Tom Untermeyer, Chief Operations Officer and Chief Technology Officer. “Our work with Hydrenesis to develop the new technologies has strengthened our engineering capabilities, and we look forward to ongoing co-development work with Hydrenesis to enhance our IP portfolio even further.”
Gerald Easterling, Chief Executive Officer, added, “As we continue to expand our shrimp production capabilities, having additional IP such as this will only strengthen our presence both domestically and internationally, as we expand over the next several years.”
David Antelo, Hydrenesis President and CEO, also added, “The cohesive relationship between the NaturalShrimp and Hydrenesis engineering teams has accelerated the development of our technologies as we focus on an aggressive growth trajectory. This joint patent represents more than 12 months of collaboration and is expected to add shareholder value as the commercialization phases unfold.”
About NaturalShrimp
NaturalShrimp, Inc. is a publicly traded aquaculture Company, headquartered in Dallas, with production facilities located near San Antonio, Texas and Webster City, Iowa. The Company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp. For more information visit www.naturalshrimp.com.
Forward-Looking Statements
This press release contains a number of forward-looking statements that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2021, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.
Investor Relations Contact
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
SHMP@mzgroup.us
FAQ
What is the recent patent application by NaturalShrimp (SHMP) about?
How does the new technology from NaturalShrimp impact aquaculture?
What are the implications of the patent for NaturalShrimp's shareholders?
Where are NaturalShrimp's production facilities located?
What is the significance of the collaboration with Hydrenesis for SHMP?
